Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases by Lesslie, D P et al.
Vascular endothelial growth factor receptor-1 mediates migration
of human colorectal carcinoma cells by activation of Src family
kinases
DP Lesslie III
1,2, JM Summy
2, NU Parikh
2, F Fan
2, JG Trevino
1,2, TK Sawyer
3, CA Metcalf III
3, WC Shakespeare
3,
DJ Hicklin
4, LM Ellis
1,2 and GE Gallick*,2
1Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA;
2Department of
Cancer Biology, 1515 Holcombe Boulevard, Houston, TX, USA;
3Ariad Pharmaceuticals, Cambridge, MA, USA;
4ImClone Systems, New York, NY, USA
Vascular endothelial growth factor (VEGF) is the predominant pro-angiogenic cytokine in human malignancy, and its expression
correlates with disease recurrence and poor outcomes in patients with colorectal cancer. Recently, expression of vascular endothelial
growth factor receptors (VEGFRs) has been observed on tumours of epithelial origin, including those arising in the colon, but the
molecular mechanisms governing potential VEGF-driven biologic functioning in these tumours are not well characterised. In this
report, we investigated the role of Src family kinases (SFKs) in VEGF-mediated signalling in human colorectal carcinoma (CRC) cell
lines. Vascular endothelial growth factor specifically activated SFKs in HT29 and KM12L4 CRC cell lines. Further, VEGF stimulation
resulted in enhanced cellular migration, which was effectively blocked by pharmacologic inhibition of VEGFR-1 or Src kinase.
Correspondingly, migration studies using siRNA clones with reduced Src expression confirmed the requirement for Src in VEGF-
induced migration in these cells. Furthermore, VEGF treatment enhanced VEGFR-1/SFK complex formation and increased tyrosine
phosphorylation of focal adhesion kinase, p130 cas and paxillin. Finally, we demonstrate that VEGF-induced migration is not due, at
least in part, to VEGF acting as a mitogen. These results suggest that VEGFR-1 promotes migration of tumour cells through a Src-
dependent pathway linked to activation of focal adhesion components that regulate this process.
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Three distinct receptor tyrosine kinases bind vascular endothelial
growth factor (VEGF): vascular endothelial growth factor receptor
(VEGFR)-1 (Flt-1), VEGFR-2 (Flk-1/KDR) and VEGFR-3 (Flt-4).
Vascular endothelial growth factor receptor 1 and VEGFR-2 are
expressed primarily on vascular endothelial cells, while VEGFR-3
is expressed primarily on lymphatic endothelial cells and regulates
lymphangiogenesis (Irrthum et al, 2000). Vascular endothelial
growth factor receptor 2 is believed to be the major mediator of
angiogenesis in human malignancy, as it regulates activation of
downstream effector molecules such as phosphoinositide 3-kinase
and AKT, and potentiates endothelial differentiation, DNA
synthesis and proliferation (Waltenberger et al, 1994; Meyer and
Rahimi, 2003). Vascular endothelial growth factor receptor 1
appears to function as a VEGF ‘sink’ during developmental
vasculogenesis, but may contribute to angiogenesis in pathologic
states such as ischaemia or malignancy (Hiratsuka et al, 1998,
2001; Carmeliet et al, 2001; Hayashibara et al, 2001).
In addition to their expression on endothelial cells, VEGFRs are
also expressed on cells of haematopoietic origin and have recently
been demonstrated on a variety of tumour types, including
prostate, ovarian, melanoma, non-small-cell lung, pancreatic and
colon (Decaussin et al, 1999; Ferrer et al, 1999; Masood et al, 2001).
While the functions of VEGFRs on tumour cells are not completely
understood, the concomitant production of VEGF and VEGFR
expression by tumour cells suggests the possibility that these
receptors mediate biologic functions in tumour cells. Indeed, in
cancers of the breast and skin (melanoma) and in some
leukaemias, VEGF/VEGFR autocrine signalling loops have been
identified (Bellamy et al, 1999; Dias et al, 2000, 2001; Lacal et al,
2000), but the elucidation of the contribution of individual VEGF/
VEGFR family members to biologic functions mediated by
individual receptors is only beginning to emerge. In a recent
work, Wang et al (2004) demonstrated differential regulation of
lymphoma xenografts utilising species-specific receptor antibodies
to VEGFR-1 and VEGFR-2. In that study, targeting tumour-
associated VEGFR-1 (human xenografted cells) increased apopto-
sis and diminished tumour growth, while targeting host (i.e.
murine) VEGFR-2 diminished microvascular density (Wang et al,
2004). Also, inhibition of VEGFRs with a synthetic binding
antagonist inhibited growth in xenograft models of colon and
other tumours (Ueda et al, 2005). Individual receptor ligands
may elicit different biologic responses as well. In PlGF /  mice,
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sVEGF-B (another VEGFR-1 ligand) failed to rescue vascular
development, suggesting that differential responses occur depending
on which ligand binds the receptor in vivo (Carmeliet et al,2 0 0 1 ) .
Signalling pathways mediated by VEGFRs in both endothelial
and tumour cells are now being delineated. In endothelial cells, the
Src family kinases (SFKs), Src and Yes are required for VEGF-
induced vascular permeability and survival (Eliceiri et al, 1999).
Likewise, VEGF-induced Src activation and signalling has been
reported in Kaposi’s sarcoma cells (Munshi et al, 2000). However,
the possibility that VEGFRs require SFKs to mediate their biologic
effects in other tumours has not been established.
When bound to receptor protein tyrosine kinases, SFKs become
activated. Activation of SFKs has been implicated in progression
and metastasis of a variety of solid tumours (reviewed by Summy
and Gallick, 2003). Experiments in colorectal cancer have
demonstrated increasing Src kinase activity with progression from
adenoma to dysplasia to carcinoma and, finally, to metastatic
disease (Talamonti et al, 1993), suggesting a role for Src in
regulating colon tumour progression. Additionally, Src kinase
activity and VEGF have both been associated with poor prognosis
in patients with advanced colorectal cancer (Takahashi et al, 1997;
Werther et al, 2000; Allgayer et al, 2002). Thus, the potential of
VEGFRs to signal through SFKs in colorectal cancer may be of
clinical significance.
The purpose of this study was to determine whether SFKs must
be activated in order for VEGFRs to mediate biologic effects. We
tested the effects of VEGFR signalling through SFKs on cellular
migration and proliferation in human colorectal cancer cells. We
found that migration, but not proliferation, was significantly
increased, suggesting the potential role of VEGFR-1 expression in
tumour progression in these cells.
MATERIALS AND METHODS
Cell culture
HT29 cells derived from a human colon adenocarcinoma were
maintained as a subconfluent monolayer in Dulbecco’s modified
Eagle’s medium (DMEM/F12) with Earle’s salts and 2mM
glutamine (Life Technologies, Inc., Grand Island, NY, USA)
supplemented with 10% foetal bovine serum (Hyclone Labora-
tories, Logan, UT, USA) without antibiotics and incubated in 5%
CO2/95% air at 371C. Highly metastatic KM12L4 human colorectal
carcinoma (CRC) cells were kindly provided by IJ Fidler, PhD,
DVM (The University of Texas MD Anderson Cancer Center,
Houston, TX, USA). Cells were cultured and maintained in
minimal essential medium (MEM) supplemented with 10% foetal
bovine serum (Hyclone Laboratories), 2Uml
 1 of a penicillin–
streptomycin mixture (Flow Laboratories, Rockville, MD, USA),
vitamins (Life Technologies, Inc., Grand Island, NY, USA), 1mM
sodium pyruvate, 2mML -glutamine and nonessential amino acids,
and incubated in 5% CO2/95% air at 371C.
Creation of siRNA expression plasmids silencing Src gene
expression
SiRNA expression plasmids were created using the Ambion
pSilencer 1.0-U6 (Austin, TX, USA) according to the manufac-
turer’s directions. c-Src specific target sequences were designed
using the Ambion siRNA web design tool. The two target
sequences utilised were (52–71bp) 50-AACAAGAG CAAGCC
CAAGGAT-30 and (226–244bp) 50-AAGCTGTTCGGAGGCTT
CAAC-30. Oligonucleotides corresponding to these sequences with
flanking Apa1( 5 0) and EcoR1 (30) ends were purchased from
Invitrogen/Life Technology (Carlsbad, CA, USA) and ligated into
the expression plasmid at compatible sites. Constructs were
confirmed by DNA sequencing. HT29 cells were then transfected
with 500ng of each siRNA plasmid and 100ng of pcDNA G418
resistance promoter-less plasmid for selection of transfectants.
Cells were then grown in selective media containing G418 as
described previously (Ahmad et al, 2001). Negative controls were
transfected with empty vector target sequences and pcDNA
plasmids at identical concentrations. Total c-Src expression levels
in siRNA clones were determined by Western blot analysis.
Inhibitors/recombinant growth factors
The novel, selective, potent Src kinase inhibitor, AP23464 (O’Hare
et al, 2004; Brunton et al, 2005; Corbin et al, 2005; Summy et al,
2005), or the commercially available Src kinase inhibitor, 4-amino-
5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine (PP2)
(Calbiochem, San Diego, CA, USA) suspended in 1% dimethyl
sulphoxide (DMSO) at desired concentrations and the VEGFR-1
monoclonal blocking antibody IMC-18F1 were used in this study.
The recombinant human growth factors VEGF-A and VEGF-B
(R&D Systems, Minneapolis, MN, USA) were used at 10 and
50ngml
 1, respectively, unless noted otherwise.
Cell lysis
Cells in log growth phase at 50% confluency were serum starved
overnight and exposed to the VEGFR-1 blocking antibody IMC-
18F1 (20mgml
 1), or AP23464 (1mM) was added to culture media
for 1h at 371C. Recombinant VEGF-A or -B or PBS control was
then added at the desired concentration, and, at the desired time,
cells were rinsed twice with ice-cold PBS and then lysed with RIPA-
B lysis buffer (20mM sodium phosphate, 150mM NaCl, 5mM
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate) supplemen-
ted with one tablet complete mini-EDTA protease inhibitor
cocktail (Roche Diagnostic, Manheim, Germany) and 1mM sodium
orthovanadate (pH 7.4). Cells were harvested with the aid of a
rubber policeman, clarified by centrifugation at 13000g for 15min
at 41C, and prepared for Western blot analysis or immunopreci-
pitation, as described previously (Windham et al, 2002).
Immunodepletion assay
Cleared cell lysates (250mg protein) were incubated overnight at
41C with 10ml anti-VEGFR-1 antibody (Oncogene Research
Products, Cambridge, MA, USA) or 10ml antimouse IgG (Organon
Teknika, Durham, NC, USA). Immune complexes were formed by
the addition of 50ml protein A:G agarose beads for 2h at 41C. The
remaining soluble lysates were centrifuged at 13000g for 2min
and the supernatants were collected for immunoblotting.
Immunoprecipitation and immune complex kinase assay
Cleared cell lysates (500mg protein) were incubated overnight at
41C with 10ml of Src monoclonal antibody 327 (Oncogene
Research Products, Cambridge, MA, USA), 10ml Yes antibody
1B7 (WAKO Biologicals, Richmond, VA, USA) or 6ml focal
adhesion kinase (FAK) antibody (clone 2A7, Upstate Biotechno-
logy, Lake Placid, NY, USA). Immune complex kinase assays were
performed as described previously (Windham et al, 2002). Briefly,
immune complexes were formed by the addition of 10ml of rabbit
antimouse IgG (Organon Teknika, Durham, NC, USA) for 2h,
followed by 50ml of 10% (vv
 1) formalin-fixed Pansorbin
(Staphylococcus aureus, Cowan strain; Calbiochem, La Jolla, CA,
USA) for 60min. Pellets were then washed three times in a buffer
consisting of 0.1% Triton X-100, 150mM NaCl and 10mM sodium
phosphate. Reactions were initiated at 221C by the addition of
10mCi of [g
32P]ATP, 10mM Mg
2þ and 100mM sodium ortho-
vanadate in 20mM HEPES buffer to each sample. To analyse
phosphorylation of an exogenous substrate, 10mg of rabbit muscle
enolase (Sigma-Aldrich, St Louis, MO, USA) was added to the
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sreaction buffer. After 10min, reactions were terminated by the
addition of SDS sample buffer. Proteins were separated by SDS–
PAGE on 8% polyacrylamide gels, and radioactive proteins were
detected by autoradiography.
Immunoblotting
Proteins (50mg) from clarified cell lysates were separated via 8%
SDS–PAGE and electroblotted onto polyvinylidene difluoride
membranes (Amersham Corp., Chicago, IL, USA). The membranes
were blocked with Tris-buffered saline/Tween (0.15)þ5% dried
milk for 30min at room temperature and probed with the desired
primary antibody diluted 1:1000 in blocking buffer overnight at
41C. Membranes were probed with antibodies to Src mAb#327
(Oncogene Research Products), Yes Ab 1B7 (WAKO Biologicals),
phospho FAK
Y397 (Biosource International, Camarillo, CA, USA),
phospho FAK
Y861 (Biosource International), FAK (BD Transduc-
tion, San Jose, CA, USA), Akt (5G3, Cell Signaling Technology,
Beverly, MA, USA), phospho-Akt
S473 (Cell Signaling Technology),
p42/44 Erk MAPK (Cell Signaling Technology), phospho-p42/44
Erk
T202/Y204 (Cell Signaling Technology), VEGFR-1 (Oncogene
Research Products), paxillin (Cell Signaling Technology), phos-
pho-paxillin
Y118 (Cell Signaling Technology), p130
cas (BD Trans-
duction), phospho-p130
cas/Y165 (Cell Signaling Technology),
phosphotyrosine (4G10, Upstate, Lake Placid, New York, NY,
USA) and vinculin (Sigma-Aldrich). Primary antibody incubation
was followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (Bio-Rad goat anti-mouse, sheep
anti-rabbit or rabbit anti-goat; Bio-Rad laboratories, Hercules, CA,
USA) diluted 1:3000 in blocking buffer for 1h at room
temperature. Proteins were visualised with electrochemilumines-
cence detection reagents (Perkin-Elmer, Boston, MA, USA) and
detected with autoradiography.
Proliferation assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(M2128) (Sigma Chemical Corp., St Louis, MO, USA) was prepared
by dissolving 5mg M2128 in 1ml PBS. The solution was protected
from light and stored at 41C. To determine proliferation, HT29
cells (1.5 10
3 cells) were seeded into 96-well plates in quintupli-
cate and allowed to adhere overnight in 10% complete DMEM/F12.
The medium was then removed and replaced with 0.2ml of media
containing VEGF-A supplemented with solvent control, IMC-18F1
or AP23464 and allowed to incubate at 371C. At the desired time
point, 50ml of prepared MTT solution was added to each well and
incubated at 371C for 2h. The media was removed carefully and
the cells were solubilised in 0.2ml DMSO. Plates were read using
spectrophotometric analysis at a wavelength of 570nm using the
TECAN Genios plate reader and Magellan version 4.0 software.
Results are representative of three independent experiments.
Migration assay
The modified Boyden chamber migration assay was used as
described previously (Minard et al, 2005). Cells (2.5 10
5 cells)
were suspended in the upper well of the migration chamber
(control inserts, 8mm pore size; Becton-Dickinson, Bedford, MA,
USA) in 0.5ml of serum-free media. The lower chamber was filled
with 0.75ml of media with VEGF-A (10ngml
 1) supplemented
with DMSO control, IMC-18F1 (20mgml
 1) or AP23464 (1mM).
After 72h of incubation, the nonmigratory colon carcinoma cells
on the upper filter surface were removed with a cotton swab, and
cells that had migrated to the lower filter were fixed and stained
with HEMA 3 (Biochemical Sciences, Swedesboro, NJ, USA)
according to the manufacturer’s instructions. The migratory cells
were counted under a microscope at  100 magnification. Cell
images were obtained using a Sony PXC-990 3CCD colour video
camera (Sony of America, New York, NY, USA). Cells were
counted in five random fields per insert in triplicate.
Statistical analyses
Statistical differences among groups were examined using the
two-tailed Student’s t-test. Po0.05 was considered statistically
significant.
RESULTS
VEGF induces SFK activation in human CRC cells
A variety of growth factors are known to induce SFK activation in
endothelial cells. We examined HT29 and KM12L4 human CRC
cells to determine whether Src and Yes, the SFK members
principally expressed in these cells (Cartwright et al, 1989; Park
et al, 1993), are activated by VEGF-A. As measured by immune
complex kinase assay, treatment of HT29 cells with VEGF-A
(10ngml
 1) increased both Src and Yes kinase activity in a time-
dependent manner (Figure 1A). Maximal activation (B2.5-fold
increase) was observed within 15min, which is consistent with Src
activation by a number of ligands. Src expression did not change
during the time period analysed, consistent with our postulate that
VEGF-A increases specific activity of these SFKs. As shown in
Figure 1B, VEGF-A also activates SFKs in a dose-dependent
0
0
0 1 10 25 50
5 m
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VEGF-A (ng ml–1)
VEGF-A (10 ng ml–1)
Yes autophosphorylation
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Src Y416
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Figure 1 Effect of VEGF on SFK activity in human CRC cell lines. (A)
Serum-starved HT29 cells at 50% confluency were untreated (0) or
stimulated with VEGF-A for 5, 10 and 15min. Cell lysates were
immunoprecipitated with anti-Src or anti-Yes antibodies and subjected to
immune complex kinase assays (top two panels) or Western blotting with
the phospho-specific anti-Src Y416 antibody. Western blotting (following
immunoprecipitation) with anti-Src antibody demonstrates equivalent total
Src expression (bottom panel). (B) Serum-starved HT29 cells at 50%
confluency were untreated (0) or stimulated with indicated concentrations
of VEGF-A for 15min. Cell lysates were immunoprecipitated with anti-Src
or anti-Yes antibodies and subjected to immune complex kinase assay. (C)
KM12L4 cell lysates were prepared and immunoblotted with SrcY416
antibodies and stripped and reprobed with total Src antibodies as described
above.
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smanner in HT29 cells, with maximal kinase activation observed at
25ngml
 1. Likewise, treatment of KM12L4 human CRC cells with
VEGF-A (10ngml
 1) induced a similar increase in SFK activation
(Figure 1C) as that observed in HT29 cells.
VEGF-induced SFK activation occurs through VEGFR-1 in
HT29 cells
As reported previously, HT29 cells express VEGFR-1 but not
VEGFR-2 or VEGFR-3 (Fan et al, 2005). To demonstrate VEGFR-1
activation and specificity of the monoclonal VEGFR-1 blocking
antibody, IMC-18F1, tyrosine phosphorylation of VEGFR-1 was
determined by Western blotting. As presented in Figure 2A, VEGF-
A treatment resulted in marked increase in tyrosine phosphoryla-
tion of a 180kDa cellular protein, which was effectively blocked by
pretreatment with IMC-18F1, confirming the ability of IMC-18F1
to inhibit VEGFR-1 activation without altering VEGFR-1 expres-
sion levels. Next, to determine whether activation of SFKs was
mediated by VEGFR-1, SFK activity with VEGF-A (ligand for both
VEGFR-1 and -2) and the VEGFR-1 specific ligand VEGF-B was
examined in the presence or absence of IMC-18F1. As shown in
Figure 2B and C, VEGF-A and -B induced similar SFK activation at
the doses indicated; however, pre-incubation of HT29 cells with
IMC-18F1 (20mgml
 1) abrogated Src and Yes activation by both
VEGF-A and -B, demonstrating that functional VEGFR-1 is
required for VEGF-mediated SFK activation.
Increased activity of SFKs usually results from direct association
with the cognate receptor. To determine whether VEGF induces
SFK/VEGFR-1 complexes, co-immunoprecipitation experiments
were performed with VEGF stimulation in the presence or absence
of VEGFR-1 blocking antibody. As demonstrated in Figure 2D,
VEGF greatly enhanced SFK/VEGFR-1 complex formation, and
this association was effectively blocked by pretreatment with IMC-
18F1. Immune complexes were not detectable when using an
irrelevant IgG antibody (data not shown). Taken together, these
results suggest that increased SFK activity may result from direct
interaction with VEGFR-1, though other mechanisms might
account for increased Src activity as well.
VEGF induces migration of human CRC cells
Src family members have been implicated in numerous biologic
activities, including proliferation and migration (reviewed by
Brown and Cooper, 1996; Thomas and Brugge, 1997). To identify
the potential biologic effects mediated by VEGFR-1 expression, we
first assessed cellular migration in response to VEGF-A, utilising a
modified Boyden chamber as described in Materials and Methods
(Figure 3). As demonstrated in Figures 3B and D, VEGF-A
treatment of HT29 and KM12L4 human CRC cells resulted in a
five- and three-fold increases in cellular migration, respectively,
over nontreated control cells (Po0.001). Pharmacologic blockade
of VEGFR-1 with IMC-18F1 or Src kinase inhibition with AP23464
or PP2 completely inhibited VEGF-induced migration in both cell
lines (Po0.001), again demonstrating the requirement of SFK
activation through VEGFR-1 in this process.
Effects of Src-targeted siRNA on VEGF-induced migration
of CRC
To independently confirm the requirement for Src in mediating
VEGF-A-induced migration, the ability of this ligand to affect
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Figure 2 Requirement for VEGFR-1 for Src activation by VEGF-A and
VEGF-B. (A) Lysates from VEGF-treated cells in the presence or absence of
the VEGFR-1 blocking antibody, IMC-18F1, following immunodepletion
with anti-VEGFR-1 antibody (first lane) or nonspecific IgG (second and
third lanes) were prepared, and the resultant supernatants were subjected
to Western blotting with anti-phosphotyrosine antibody or anti-VEGFR-1
antibody. (B, C) Serum-starved HT29 cells at 50% confluency were
pretreated with IMC-18F1 or PBS control for 1h and were untreated (0)
or stimulated with VEGF-A or VEGF-B for 10, 15 and 30min. Cell lysates
were immunoprecipitated with anti-Src or anti-Yes antibodies and
subjected to immune complex kinase assay or subjected to Western
blotting with anti-Src, anti-Yes or anti-VEGFR-1 antibodies to demonstrate
the lack of effect on expression of these proteins. (D) Lysates from VEGF-
A-treated cells in the presence or absence or IMC-18F1 were
immunoprecipitated with anti-VEGFR-1 antibody. The resultant immuno-
precipitates were run on SDS–PAGE and subjected to Western blotting
with antibodies to Src, Yes or VEGFR-1.
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smigration in HT29 clones reduced in Src by stable expression of an
antisense expression vector was determined. As shown in
Figure 4A, two independent clones (siRNA cl.18 and 23) were
reduced by more than 80% in Src expression. These cells were
considerably reduced in their migratory abilities (Figure 4B),
consistent with Src being important in cellular migration, and
addition of VEGF-A did not increase migratory capability of these
cells (Figure 4C), providing further evidence that VEGF mediates
migration through Src activation. Basal proliferation of these cells
as determined by MTT assay did not differ significantly from
nontransfected parental cells (data not shown).
VEGF activates FAK, p130
cas and paxillin in HT29 cells
In epithelial and fibroblast cells, migration is regulated, in part, by
activation of FAK. Recent studies in endothelial cells have
implicated FAK as required for VEGFR-1-induced tubulogenesis
(Maru et al, 2001). Src/FAK activation then leads to phosphoryla-
tion of both paxillin and p130
cas. To determine if FAK were
activated upon treatment of HT29 cells with VEGF, both FAK
immune complex kinase assays and Western blot analysis for
specific FAK phosphorylation sites were performed as described in
Materials and Methods. As presented in Figure 5A, VEGF
treatment of HT29 cells increased both autophosphorylation of
FAK and phosphorylation of the exogenous substrate enolase two-
fold at 30min. As enolase phosphorylation may also result from
Src being immunoprecipitated in the immune complexes, we
directly examined phosphorylation of Y861 and Y397 in response
to VEGF stimulation of HT29 cells. Phosphorylation of Y861, and
to a lesser extent Y397, was increased, and these increases were
blocked by prior addition of IMC-18F1. These findings are
consistent with previous experimental work in VEGFR-1 over-
expressing fibroblasts (Maru et al, 2001) and suggest crosstalk
between VEGFR-1 and FAK in HT29 cells. As shown in Figure 5B
and C, VEGF treatment of HT29 cells also increased tyrosine
phosphorylation of both paxillin and p130
cas. Maximal phosphor-
ylation occurred within 15–30min, consistent with the kinetics of
Src and Yes activation. Pretreatment of HT29 cells with IMC-18F1
effectively blocked FAK, paxillin and p130
cas phosphorylation,
confirming the requirement of VEGFR-1 for VEGF-induced
activation of these substrates. Together, these results suggest that
a VEGFR-1/SFK complex interacts with components of focal
adhesions, thus mediating cellular migration in HT29 cells.
VEGF does not induce proliferation in HT29 cells
Finally, to determine if VEGF-induced migration could be
accounted for, at least in part, by VEGF acting as a mitogen, we
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 1), the
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modified Boyden chamber containing VEGF-A (10ngml
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Figure 4 Effects of Src-targeted siRNA on VEGF-induced CRC
migration. (A) HT29 parental cells and stable G418-resistant clones
expressing either empty vector (siRNA control) or Src-targeted siRNA
were subjected to Western blot analysis with antibodies to total Src.
Membranes were stripped and reprobed with anti-vinculin antibody as a
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 1) or 10% FBS for 72h. (B) Representative photos of VEGF-A-
treated cells ( 100 magnification). (C) Quantitation of migrated cells.
*Po0.001 vs VEGF-treated siRNA control.
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HT29 cells. As shown in Figure 6, exogenous VEGF-A had no effect
on HT29 cell proliferation, as determined by MTT assay. Likewise,
pretreatment of HT29 cells with IMC-18F1 did not decrease
proliferation. Consistent with these findings, VEGF-A treatment of
HT29 cells induced minimal to no activation of Erk 1/2 or Akt, as
assessed by Western blotting for phosphorylated (active) forms of
these signalling enzymes (data not shown).
DISCUSSION
Our findings of VEGF-induced SFK activation and enhanced
cellular migration in human CRC cells demonstrate that functional
VEGFR-1 mediates intracellular signalling and biologic behaviour
in these cells. Src family kinase activation in response to VEGF has
been observed in cells of endothelial origin expressing VEGFRs,
and SFK members have been shown to associate with VEGFRs
upon activation (Chou et al, 2002). In contrast to work in
endothelial cells where Src preferentially associates with VEGFR-2
and Yes and Fyn with VEGFR-1, we observed Src and Yes kinase
complex formation with VEGFR-1 upon VEGF stimulation,
suggesting that at least in these tumour cells, association of SFKs
with VEGFR-1 may be more promiscuous than in normal
endothelial cells.
The ability of VEGF to mediate particular biologic functions
appears to be cell type specific, as does expression of VEGF
receptor subtypes. Many cell types exhibiting increased prolifera-
tion in response to VEGF express both VEGFR-1 and -2, or are of
nonepithelial origin. The significance of aberrant expression of
VEGFR-1 alone on tumours of epithelial origin remains unclear,
but a recently published work found a similar lack of proliferation
in VEGF-stimulated colon cancer cells expressing VEGFR-1 (Fan
et al, 2005).
Interestingly, we observed a robust increase in cellular migra-
tion and tyrosine phosphorylation of FAK, paxillin and p130
cas in
CRC cells with VEGF stimulation, which appears to require
VEGFR-1. This is consistent with prior reports suggesting that
VEGFR-1 regulates cellular migration, while VEGFR-2 mediates
activation of the MAPK pathway and cellular proliferation
(Barleon et al, 1996). Further, our finding of VEGF-induced FAK
phosphorylation, resulting in its increased activation, is consistent
with previous studies on VEGFR-1-overexpressing fibroblasts
(Maru et al, 2001). This result suggests an interaction between
VEGFR-1 and FAK in HT29 cells. Whether this interaction is direct
or indirect remains to be determined.
Vascular endothelial growth factor is a pleuripotent cytokine
that induces angiogenesis, proliferation, migration, differentiation
and vascular permeability in endothelial cells (Leung et al, 1989;
Millauer et al, 1993; Neufeld et al, 1999). It is secreted by most, if
not all solid tumours, including those arising in colon, where it is
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Figure 5 Effects of VEGF on phosphorylation of FAK, p130
cas and
paxillin in CRC. Serum-starved HT29 cells at 50% confluency were
pretreated with the VEGFR-1 blocking antibody (IMC-18F1) or PBS control
for 1h and were untreated (0) or stimulated with VEGF-A for 10, 15 and
30min. Cell lysates were immunoprecipitated with anti-FAK antibody and
subjected to immune complex kinase assay with enolase as an exogenous
substrate or subjected to Western blotting with anti-phospho-FAK Y861,
anti-phospho-FAK Y397 or anti-FAK antibodies as indicated (A), run on
SDS–PAGE and subjected to Western blotting with anti-phospho-p130
cas
or anti-p130
cas antibodies (B) or subjected to Western blotting with anti-
phospho-paxillin or anti-paxillin antibodies (C). Western blot for vinculin is
included to demonstrate equivalent protein loading.
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Figure 6 Effects of VEGF on CRC proliferation. HT29 cells (2 10
3)i n
96-well plates in serum-free media were untreated or treated with VEGF-A
(10ngml
 1) in the presence of AP23464 (1mM) or IMC-18F1 (20mgml
 1)
and proliferation was determined by MTT assay as described in Materials
and Methods. Bars represent standard error of the mean. Results are
representative of three independent experiments.
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Figure 7 Model by which Src and VEGF contribute to tumour
progression and metastasis through activities in both tumour and
tumour-associated endothelial cells. In tumour cells (left) Src activation is
frequent, resulting from overexpression of growth factor receptors, FAK
and deregulated transcription (A). Src activation increases VEGF expres-
sion from tumour cells (B), leading to binding of VEGFR-1 (C), association
with and further activation of Src (D), and the subsequent autocrine loop
contributes to tumour cell migration through FAK activation (E). Vascular
endothelial growth factor produced by tumour cells also binds VEGF
receptors on endothelial cells (F), leading to association and activation of
Src in these cells (G) and leading to increased permeability through VE
cadherin phosphorylation affecting tumour cell extravasation (H), a process
critical for permeability and tumour cell extravasation (I). Thus, inhibitors of
VEGF, VEGFR-1 and Src may have therapeutic efficacy due to their effects
in both normal and tumour cells.
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sthe principal mediator of tumour angiogenesis and its expression
correlates with both disease recurrence and poor prognosis
(Takahashi et al, 1997; Werther et al, 2000). As anti-VEGF therapy
has demonstrated efficacy in patients with advanced CRC (Hurwitz
et al, 2004), further study of VEGF/VEGFR interactions in
endothelial and, perhaps, tumour cells is warranted (Figure 7).
Here we have shown that VEGFR-1 participates in intracellular
signal transduction and mediates biologic activity, specifically
cellular migration, in human CRC cells. The expression of this
receptor protein tyrosine kinase in tumour cells may further
amplify signalling pathways already activated in colon tumour
cells. Thus, VEGFR-mediated signalling offers novel targets for
therapeutic interventions, either by targeting the receptor itself or
important downstream mediators, such as Src. As Src activity has
been shown to regulate VEGF expression, particularly under
hypoxic conditions, in CRC cells (Ellis et al, 1998), the existence of
an autocrine signalling loop capable of enhancing tumour survival
and progression is intriguing. Delineating the mechanisms by
which individual receptor tyrosine kinases mediate biologic
activity in tumour cells is crucial for defining tumour-specific
targets for optimal therapy. As recent work has demonstrated the
presence of VEGFR-1 in multiple colon cancer cell lines and in
both primary and metastatic tumour samples (Fan et al, 2005),
VEGFR-1 may be a relevant clinical target, not only for its
expression in endothelial cells but also for its expression/function
in tumour cells.
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